Pub Date : 2019-09-01DOI: 10.1136/lupus-2019-la.18
H. Prüss
1. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78(6):736–45. 2. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73(6):958–67. 3. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis 2018;77(10):1432–39. 4. El-Sherbiny YM, Md Yusof MY, Psarras A, et al. B cell tetherin: a flow-cytometric cell-specific assay for response to Type-I interferon predicts clinical features and flares in SLE. bioRxiv 2019:554352.
1. Fanouriakis A, Kostopoulou M, Alunno A等。2019更新EULAR关于系统性红斑狼疮管理的建议。中国生物医学工程学报，2019;38(6):736 - 745。2. 范浩文，莫斯卡，波提斯，等。系统性红斑狼疮的靶向治疗:来自国际工作组的建议。中国生物医学工程学报，2014;33(6):958 - 967。3.Md Yusof MY, Psarras A, El-Sherbiny YM，等。自身免疫性结缔组织疾病在高危人群中的预测:一种新的干扰素状态双评分系统的预后价值中华医学杂志，2018,37(10):1432 - 1439。4. El-Sherbiny YM, Md Yusof MY, Psarras A，等。B细胞栓素:对i型干扰素反应的流式细胞术细胞特异性测定预测SLE的临床特征和耀斑。bioRxiv 2019:554352。
{"title":"01 Mind antibodies and CNS involvement in SLE: differential diagnoses","authors":"H. Prüss","doi":"10.1136/lupus-2019-la.18","DOIUrl":"https://doi.org/10.1136/lupus-2019-la.18","url":null,"abstract":"1. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78(6):736–45. 2. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73(6):958–67. 3. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis 2018;77(10):1432–39. 4. El-Sherbiny YM, Md Yusof MY, Psarras A, et al. B cell tetherin: a flow-cytometric cell-specific assay for response to Type-I interferon predicts clinical features and flares in SLE. bioRxiv 2019:554352.","PeriodicalId":280862,"journal":{"name":"Hot Topic Lecture","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125888727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
use of antibiotics is not recommended, nevertheless a low index of suspicion to diagnose an infection – including possible Pneumocystis pneumonia – and commence antibiotics promptly is warranted in high-risk groups including elderly or neutropenic patients, those with comorbidities (e.g. diabetes) or who are receiving glucocorticoids. Osteoporosis and fragility fractures are potentially avoidable and readily treated comorbidities in patients with SLE. 14 Factors impacting adversely on bone mass density, particularly chronic use of glucocorticoids, should be corrected. Osteoprotective and/or anti-osteoporotic interventions should be similar to those in the general population or patients with other chronic inflammatory disorders, yet caution is recommended in cases of kidney disease and reduced glomerular filtration rate. To this end, SLE patients should also be screened for vitamin D insufficiency, which should be corrected considering its presumed multifaceted effects on the disease.
{"title":"01 APS in SLE patients: best treatment practice","authors":"M. Khamashta","doi":"10.1136/lupus-2019-la.7","DOIUrl":"https://doi.org/10.1136/lupus-2019-la.7","url":null,"abstract":"use of antibiotics is not recommended, nevertheless a low index of suspicion to diagnose an infection – including possible Pneumocystis pneumonia – and commence antibiotics promptly is warranted in high-risk groups including elderly or neutropenic patients, those with comorbidities (e.g. diabetes) or who are receiving glucocorticoids. Osteoporosis and fragility fractures are potentially avoidable and readily treated comorbidities in patients with SLE. 14 Factors impacting adversely on bone mass density, particularly chronic use of glucocorticoids, should be corrected. Osteoprotective and/or anti-osteoporotic interventions should be similar to those in the general population or patients with other chronic inflammatory disorders, yet caution is recommended in cases of kidney disease and reduced glomerular filtration rate. To this end, SLE patients should also be screened for vitamin D insufficiency, which should be corrected considering its presumed multifaceted effects on the disease.","PeriodicalId":280862,"journal":{"name":"Hot Topic Lecture","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117273871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：